secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001628280-23-006039
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx reports FY2022 net loss $67.2M; IBSRELA sales $15.6M; XPHOZAH NDA resubmission expected early Q2 2023
--------------------------------------------------------------------------------

- Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.
- IBSRELA net product sales $15.6M for FY2022, with $8.7M in Q4; consistent prescription growth.
- Cash and investments $123.9M at Dec 31, 2022; $121.0M at Feb 28, 2023 (includes $20M ATM proceeds).
- XPHOZAH NDA resubmission on track for early Q2 2023 after productive FDA Type A meeting.
- Debt facility amended: interest-only period may extend to Mar 2025; additional $22.5M available contingent on FDA approval and revenue targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/ardx-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-006039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer